This trial is evaluating whether 67Cu-SARTATE will improve 9 primary outcomes in patients with Neuroblastoma. Measurement will happen over the course of 6 weeks.
This trial requires 34 total participants across 1 different treatment group
This trial involves a single treatment. 67Cu-SARTATE is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The data support a complex genetic background for neuroblastoma. In the majority of the children with neuroblastoma, no family history for neuroblastoma was observed. Results from a recent clinical trial suggest that genetic susceptibility to neuroblastoma may be inherited in an autosomal dominant fashion. This may apply also to some children with pheochromocytoma/parathyroid tumor, which may have similar inheritance characteristics." - Anonymous Online Contributor
"In the US, neuroblastoma is diagnosed at its more aggressive stages in whites and blacks. Most children with neuroblastoma do not live past two years, but those with poor histological features live longer. The incidence of neuroblastoma varies substantially by country, and the incidence in the United States is similar to or higher than in other industrialized countries." - Anonymous Online Contributor
"This common tumour type affects infants and children most often (up to 60 per cent of patients) and can spread in very rare cases to the brain. Although, as with many childhood cancers, treatment is usually only available in large, well equipped medical centres.\n" - Anonymous Online Contributor
"Stem cell transplantation is very effective for treating NB and is an option for children and adults. The most usual risks of this procedure are related to infections, especially encephalitis." - Anonymous Online Contributor
"The signs of neuroblastoma are related to the location of the tumor mass. Symptoms are related to the location and extent of the tumor mass, and include: abdominal discomfort or pain, nausea, vomiting, and loss of hearing." - Anonymous Online Contributor
"There is as yet no cure for neuroblastoma. This is due to the fact that the tumors can develop resistance to some of the treatments." - Anonymous Online Contributor
"Only 1 in 3 children undergoing neuroblastoma therapy currently enroll in a clinical trial. Many of these children will not benefit from treatment. Children with symptomatic disease should be considered for clinical trials. Children with minimal disease may be appropriate candidates. Children with stage 2-3 disease should be offered treatment in a clinical trial even if their disease is minimal. Children less than 18 months with stage 1-2 disease are more likely to benefit from treatment. The study of optimal radiotherapy dosage remains highly controversial." - Anonymous Online Contributor
"The chances, after the age of about 12.5 years, of developing neuroblastoma appear to be around 20 per 10 000. As a person gains height and weight they become more likely to develop neuroblastoma. The chances do not appear to increase significantly until the age of 5 or 6 years." - Anonymous Online Contributor
"Many different medications and research has been found to stop the tumor growth, and reduce the spread. There is still no consensus, and we wait for a new treatment option." - Anonymous Online Contributor
"We believe this review would be helpful to some pediatric oncology centers and hospitals who wish to improve the quality of care by choosing treatment modalities for patients with neuroblastoma." - Anonymous Online Contributor
"The high-density uptake in myeloid cells and bone marrow suggests a possible explanation for the clinical features of s-CMMs. S-s-Cu is effective for MR imaging, but is not a sufficient radiotherapy for the treatment of BM NBM." - Anonymous Online Contributor
"The primary cause of neuroblastoma is a non-hereditary genetic disorder known as neuroblastoma. This rare disorder typically affects infants who are between six months and two and a half years old. The most commonly diagnosed sites for this disease are the abdomen, the brain or nerves. Although only a few countries in the world permit testing of children, screening can identify those people in those countries who are at a higher risk of neuroblastoma later in life." - Anonymous Online Contributor